DHMEQ racemate (rel-DHMEQ) (Synonyms: rel-DHMEQ) |
| Catalog No.GC33150 |
DHMEQ racemate (rel-DHMEQ) is a NF-κB inhibitor. DHMEQ racemate (rel-DHMEQ) is less active than (-)-DHMEQ.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 287194-38-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
DHMEQ racemate is a NF-κB inhibitor. DHMEQ racemate is less active than (-)-DHMEQ.
DHMEQ racemate (DHM3EQ) and (-)-DHMEQ (DHM2EQ) inhibits TNF-a-induced NF-kB activation. (-)-DHMEQ is more potent and less toxic than DHMEQ racemate[1].
The antiarthritic effects of (-)-DHMEQ (DHM2EQ) and DHMEQ racemate (DHM3EQ) are examined on type-II collagen-induced arthritis in DBA1/J mice. This animal model is widely used for evaluation of antirheumatic drugs because of its pathological similarities to human rheumatoid arthritis. The arthritis is elicited and scored. (-)-DHMEQ markedly inhibits type-II-collagen-induced arthritis in mice, whereas DHMEQ racemate tends to only slightly inhibit it[1].
[1]. Matsumoto N, et al. Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett. 2000 May 1;10(9):865-9.
Average Rating: 5 (Based on Reviews and 25 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *